VAIA
MRTX

Virtus Alternative Investment Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-34
Closed -$7K – 249
2020
Q4 		$7K Sell
34
-33
-49% -$7.13K 0.1% 161
2020
Q3 		$11K Sell
67
-79
-54% -$10.8K 0.2% 234
2020
Q2 		$17K Buy
+146
New +$14.2K 0.27% 96

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Virtus Alternative Investment Advisers's MRTX Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 34 shares — an estimated $7K sold.

Virtus Alternative Investment Advisers first reported a position in MRTX in Q2 2020 and held it in 3 quarters. The position peaked at $17K in Q2 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 34 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $7K.
  • Virtus Alternative Investment Advisers first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • Virtus Alternative Investment Advisers's Mirati Therapeutics, Inc. Common Stock position peaked at $17K in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.